

Sister Study Breast Cancer Events (any type) <sup>1</sup> Stratified by Race/Ethnicity <sup>2</sup>: Data Release 11.0<sup>3</sup>

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 4,053)	%	N (total = 389)	%	N (total = 289)	%
<b>Breast Cancer Subtype for 1st Diagnosis</b>						
Invasive <sup>4</sup>	3,132	77.3	283	72.8	233	80.6
Ductal only (no lobular component) <sup>5</sup>	2,171	53.6	175	45.0	163	56.4
Lobular only (no ductal component) <sup>5</sup>	283	7.0	13	3.3	14	4.8
Ductal and lobular <sup>5,6</sup>	213	5.3	9	2.3	14	4.8
Inflammatory	7	0.2	3	0.8	0	0.0
Paget's	11	0.3	2	0.5	0	0.0
Phyllodes <sup>7</sup>	5	0.1	0	0.0	0	0.0
Other/unknown if ductal or lobular <sup>8</sup>	442	10.9	81	20.8	42	14.5
<i>In situ</i>	914	22.6	106	27.2	54	18.7
Ductal only (no lobular component) <sup>9</sup>	776	19.1	94	24.2	47	16.3
Lobular only (no ductal component) <sup>9</sup>	115	2.8	8	2.1	7	2.4
Ductal and lobular <sup>6,9</sup>	14	0.3	1	0.3	0	0.0
Paget's	6	0.1	0	0.0	0	0.0
Other/unknown if ductal or lobular <sup>10</sup>	3	0.1	3	0.8	0	0.0
Invasiveness unknown <sup>11</sup>	7	0.2	0	0.0	2	0.7
<b>Stage at 1st Breast Cancer Diagnosis <sup>12</sup></b>						
0	833	23.3	85	28.4	50	20.4
I	1,858	52.0	122	40.8	125	51.0
II	689	19.3	71	23.7	47	19.2
III	169	4.7	19	6.4	21	8.6
IV	22	0.6	2	0.7	2	0.8
<i>Unknown, missing, cannot stage</i>	482		90		44	
<b>Estrogen Receptor (ER) Status for 1st Breast Cancer Diagnosis <sup>12</sup></b>						
Positive	2,934	85.8	206	74.4	189	84.0
Negative	484	14.1	69	24.9	36	16.0
Borderline	3	0.1	2	0.7	0	0.0
<i>Unknown, missing, not performed</i>	632		112		64	
<b>Progesterone Receptor (PR) Status for 1st Breast Cancer Diagnosis <sup>12</sup></b>						
Positive	2,457	74.0	160	59.5	153	70.8
Negative	857	25.8	108	40.1	63	29.2
Borderline	7	0.2	1	0.4	0	0.0
<i>Unknown, missing, not performed</i>	732		120		73	

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 4,053)	%	N (total = 389)	%	N (total = 289)	%
<b>HER2 Amplification Status for 1st Breast Cancer Diagnosis</b> <sup>12</sup>						
Positive	340	11.9	33	15.2	35	17.7
Negative	2,475	86.7	183	84.3	161	81.3
Borderline	41	1.4	1	0.5	2	1.0
<i>Unknown, missing, not performed</i>	1,197		172		91	
<b>Combined ER, PR, HER2 Status</b> <sup>12</sup>						
Triple negative (ER-, PR-, and HER2-)	260	7.8	46	17.2	18	8.3
Not triple negative	3,059	92.2	222	82.8	200	91.7
<i>Unknown, missing, not performed</i>	734		121		71	
<b>Diagnosis Confirmation</b> <sup>13</sup>						
Medical	3,395	83.8	263	67.6	226	78.2
NDI Plus or death certificate	40	1.0	16	4.1	3	1.0
None	618	15.2	110	28.3	60	20.8
<b>Age (in years) at 1st Breast Cancer Diagnosis</b> <sup>14</sup>						
Under 50	341	8.4	50	12.9	36	12.5
50-64	1,708	42.1	181	46.5	163	56.4
65 and older	2,004	49.4	158	40.6	90	31.1
<b>Menopausal Status at 1st Breast Cancer Diagnosis</b>						
Pre-menopausal	573	14.1	63	16.2	59	20.4
Post-menopausal	3,480	85.9	325	83.8	230	79.6
<i>Unknown</i>	0		1		0	

Abbreviations: BrCa= Breast cancer; DCIS=Ductal carcinoma *in situ*; LCIS = Lobular carcinoma *in situ*; MR =Medical report (medical record and/or pathology report)

<sup>1</sup> Breast cancer events (any type) are defined by the following ICD10 codes: D05 (includes lobular carcinoma *in situ*, ductal carcinoma *in situ*, other and unspecified *in situ* breast carcinomas), C50 (all invasive breast cancer), and D48.6 (neoplasm of uncertain behavior of breast)

<sup>2</sup> Excludes n=1 where race/ethnicity is missing

<sup>3</sup> Data release 11.0 includes events from follow-up phases that closed on or before 9/30/2021, excluding all data from participants who have withdrawn their data from the study (n=5). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 11.0 breast cancer events (any type) exclude a) through c) below:

- a) Breast cancers diagnosed prior to participant's baseline date;
- b) Breast cancers diagnosed with unknown timing relative to baseline;
- c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out

<sup>4</sup> Includes 'presumed invasive' (i.e., a carcinoma *in situ* with positive nodes)

<sup>5</sup> Invasive Ductal only, Invasive Lobular only, and Invasive Ductal and Lobular exclude inflammatory breast cancer and Paget's

<sup>6</sup> Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g., a ductal only tumor and a lobular only tumor)

- <sup>7</sup> Phyllodes is neither ductal nor lobular; it is a sarcoma
- <sup>8</sup> Includes: a) Invasive but unknown if ductal or lobular, these are typically self-report without MR confirmation; b) Invasive type “neither ductal nor lobular, not otherwise specified”, these are typically self-report without MR confirmation; and c) Per MR, presumed invasive - *in situ* tumor, positive nodes
- <sup>9</sup> *in situ* Ductal only, *in situ* Lobular only, and *in situ* Ductal and Lobular exclude *in situ* Paget’s
- <sup>10</sup> Includes: a) *in situ* but unknown if ductal or lobular and b) *in situ* type “neither ductal nor lobular, not otherwise specified”, these are typically self-report without MR confirmation
- <sup>11</sup> Invasiveness unknown includes: a) Unknown if invasive or *in situ* and unknown if ductal or lobular; b) Ductal but unknown if invasive or *in situ*; c) Lobular but unknown if invasive or *in situ*; and d) Per MR, unable to determine if DCIS or atypical ductal hyperplasia
- <sup>12</sup> Priority for stage and ER/PR/HER2 status when diagnosis is reported by multiple sources: Medical record>Breast Cancer Follow-Up Form
- <sup>13</sup> Medical confirmation of reported breast cancer is generally from medical records but may only include pathology report; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation
- <sup>14</sup> For those missing age at diagnosis, age was imputed as the midpoint of the range of plausible ages at diagnosis